Last updated: August 1, 2026
Eraxis, the branded formulation of anidulafungin, is an intravenous echinocandin antifungal used primarily for invasive Candida infections and esophageal candidiasis. Its clinical-development program is mature, with no identified late-stage program aimed at expanding the label. Commercial value is concentrated in hospital use, while generic anidulafungin and competing echinocandins limit branded growth.
Eraxis has lost practical market exclusivity in the United States. The principal commercial risks are generic substitution, hospital formulary compression, and competition from micafungin and caspofungin rather than a new clinical entrant.
What is Eraxis and how is anidulafungin used?
Eraxis contains anidulafungin, a semisynthetic echinocandin that inhibits beta-(1,3)-D-glucan synthase, an enzyme required for fungal cell-wall formation. It is administered intravenously because oral absorption is inadequate.
The U.S. label covers:
- Candidemia and other Candida infections, including intra-abdominal abscess and peritonitis
- Esophageal candidiasis
- Use in adults and pediatric patients from 1 month of age, subject to labeled dosing and safety requirements
The standard adult regimen is a 200-mg loading dose followed by 100 mg once daily for invasive candidiasis. Esophageal candidiasis uses a 100-mg loading dose followed by 50 mg once daily. Treatment duration depends on clinical response and microbiologic clearance. Unlike caspofungin and micafungin, anidulafungin does not require hepatic dose adjustment because it undergoes slow chemical degradation rather than clinically important hepatic metabolism [1].
| Attribute |
Eraxis |
| Active ingredient |
Anidulafungin |
| Drug class |
Echinocandin antifungal |
| Route |
Intravenous |
| U.S. approval |
February 2006 |
| Original U.S. sponsor |
Pfizer |
| Main indications |
Invasive candidiasis; esophageal candidiasis |
| Adult invasive-candidiasis dose |
200 mg loading dose, then 100 mg daily |
| Adult esophageal-candidiasis dose |
100 mg loading dose, then 50 mg daily |
| Pediatric status |
Labeled for patients 1 month and older |
| Main competitors |
Cancidas, Mycamine, generic echinocandins |
| Biosimilar exposure |
None; anidulafungin is a small molecule, not a biologic |
What clinical trials support Eraxis approval?
The pivotal invasive-candidiasis trial compared anidulafungin with fluconazole in adults with candidemia and other invasive Candida infections. Anidulafungin achieved a higher global response rate at the end of intravenous therapy and at the end of treatment than fluconazole in the primary analysis population [1,2].
A randomized study in esophageal candidiasis compared anidulafungin with fluconazole. The study supported the efficacy of anidulafungin, although relapse after treatment was an important clinical consideration in the broader echinocandin class because these agents have limited activity against Candida in the esophageal lumen after treatment ends [1].
What is the current Eraxis clinical-trial pipeline?
No major active Phase 2 or Phase 3 program associated with Eraxis has been identified through June 2024. The drug is a mature hospital antifungal, and current research involving anidulafungin generally concerns:
- Comparative treatment strategies for invasive candidiasis
- Combination therapy in critically ill patients
- Step-down treatment from intravenous echinocandins to oral azoles
- Antifungal stewardship and duration of therapy
- Pediatric and neonatal candidiasis
- Real-world outcomes and antifungal resistance
- Pharmacokinetic studies in renal replacement therapy, extracorporeal support, or special populations
These studies do not represent a conventional proprietary Eraxis lifecycle program. The most commercially relevant research question is when clinicians can safely transition from an echinocandin to oral fluconazole or another oral antifungal.
How effective is anidulafungin compared with other echinocandins?
Echinocandins have broadly comparable positions in first-line treatment of invasive candidiasis. Differences in dosing, drug interactions, hepatic handling, formulation, and hospital contracting often matter more than large efficacy differences.
| Drug |
Brand |
Key practical distinction |
Typical adult invasive-candidiasis regimen |
| Anidulafungin |
Eraxis |
No routine hepatic dose adjustment; once-daily dosing |
200 mg loading, then 100 mg daily |
| Caspofungin |
Cancidas |
Weight-based dosing and hepatic dose adjustment in selected patients |
70 mg loading, then 50 mg daily |
| Micafungin |
Mycamine |
Broad hospital use; no loading dose for many indications |
100 mg daily for candidemia, depending on indication |
The Infectious Diseases Society of America recommends an echinocandin as initial therapy for most adults with candidemia and invasive candidiasis, with transition to fluconazole for clinically stable patients who have susceptible isolates and negative repeat blood cultures [3].
Anidulafungin has a favorable interaction and organ-function profile. Its disadvantages are intravenous administration, acquisition cost relative to fluconazole, and the need for inpatient or infusion-center delivery.
What is the FDA regulatory status of Eraxis?
The FDA approved Eraxis in 2006. The product was originally approved for adults with candidemia and other Candida infections and for esophageal candidiasis. Pediatric labeling was later expanded.
Eraxis is regulated as a conventional small-molecule drug. It does not use the biologics license application pathway and does not generate biosimilar litigation or biosimilar substitution risk.
The main regulatory issues are:
- Hepatic and infusion-related safety monitoring
- Appropriate use in candidemia and invasive candidiasis
- Pediatric dosing
- Antifungal susceptibility and resistance
- Stewardship-based transition to oral therapy
- Label compliance for indications and dosing
The original New Drug Application was submitted by Lilly and later associated commercially with Pfizer. Pfizer has marketed Eraxis in the United States, while anidulafungin has been sold internationally under names including Ecalta.
What is the Orange Book status of Eraxis?
Eraxis is an old small-molecule product with no meaningful remaining period of U.S. market exclusivity. The original regulatory exclusivity periods expired long ago, and generic anidulafungin products have entered the U.S. market.
For commercial purposes, the relevant Orange Book questions are:
- Whether the branded product has any active listed patents.
- Whether listed patents cover the active ingredient, formulation, or method of use.
- Whether generic ANDA applicants were required to submit Paragraph IV certifications.
- Whether any listed patents remain enforceable against a current generic applicant.
The Orange Book should be treated as the controlling source for current listed patents and exclusivity. Historical compound and formulation patents associated with anidulafungin do not create a present-day branded barrier once their terms have expired. Eraxis therefore has limited protection against generic substitution [4].
When did Eraxis lose exclusivity and when can generics launch?
Eraxis lost effective exclusivity before the current commercial period. The product was approved in 2006, and its ordinary five-year New Chemical Entity exclusivity expired in 2011. Any applicable pediatric extension would have added six months to qualifying exclusivity, but that period also expired years ago.
Generic launch risk is therefore immediate rather than date-driven. The principal launch scenarios are:
| Scenario |
Commercial effect |
| Additional generic approvals |
Lower acquisition prices and increased hospital substitution |
| Contracting by group purchasing organizations |
Reduced branded share even without full generic conversion |
| Shortage of competing echinocandins |
Temporary demand shift toward anidulafungin |
| Increased use of oral step-down therapy |
Lower total days of intravenous echinocandin therapy |
| Resistant Candida outbreaks |
Potential increase in echinocandin use, subject to susceptibility |
| Hospital budget controls |
Greater preference for the lowest-cost interchangeable product |
Are there Paragraph IV challenges to Eraxis?
Paragraph IV litigation is not a major current risk factor for Eraxis because the principal product patents and regulatory exclusivities are aged. Generic applicants may have used Paragraph IV certifications against historical listed patents, but an active litigation campaign is not central to the present commercial outlook.
The more relevant legal status is post-exclusivity generic competition. After relevant patents expire or are removed from the Orange Book, ANDA applicants can pursue approval without facing a meaningful remaining branded patent barrier.
No active high-value patent dispute has been identified as a material constraint on generic anidulafungin availability through June 2024.
What patents protect Eraxis and anidulafungin?
Eraxis historically relied on patents covering anidulafungin-related compounds, pharmaceutical compositions, and manufacturing chemistry. Those rights were associated with the drug's development history and original sponsor network, including Lilly and later commercial rights holders.
The current patent position is weak for three reasons:
- The product was approved in 2006.
- Small-molecule patent terms generally run about 20 years from the earliest effective nonprovisional filing date, subject to adjustments.
- The commercial product has been exposed to generic development for several years.
Potential historical protection categories included:
| Protection category |
Current commercial relevance |
| Anidulafungin compound claims |
Generally expired or near-expired |
| Injectable formulation claims |
Limited if listed patents have expired |
| Manufacturing-process claims |
May affect a specific process but usually do not block all ANDA products |
| Method-of-use claims |
Narrow if limited to labeled indications |
| Pediatric-use claims |
Regulatory, not durable commercial exclusivity |
| Packaging or presentation claims |
Usually weak against generic substitution |
A patent-by-patent legal opinion requires a current Orange Book and prosecution-history review. The business conclusion is clearer: Eraxis does not have a durable, high-strength U.S. patent estate comparable to a recently launched specialty drug.
How strong is the Eraxis patent estate?
The Eraxis patent estate is commercially weak in the United States and likely offers limited leverage in Europe and other mature markets. Any remaining rights are more likely to concern manufacturing, specific formulations, or jurisdictional remnants than the core active ingredient.
| Patent-estate factor |
Assessment |
| Core compound protection |
Expired or commercially exhausted |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Limited practical value |
| Method-of-use protection |
Narrow and unlikely to block broad generic use |
| Manufacturing barriers |
Potentially relevant to cost or process design, not a complete market block |
| Litigation leverage |
Low |
| Generic entry risk |
High |
| Geographic variation |
Possible in countries with different patent histories |
What is the Eraxis market size and commercial outlook?
Eraxis-specific revenue is not generally reported as a separate line item by Pfizer. Public company disclosures typically aggregate products within broader pharmaceutical portfolios. As a result, credible standalone Eraxis revenue figures are not available from audited public reporting.
The product's market is shaped by hospital antifungal utilization rather than consumer demand. Revenue exposure is concentrated in:
- Intensive-care units
- Hematology and oncology hospitals
- Transplant centers
- Surgical and intra-abdominal infection services
- Patients with candidemia who cannot initially receive fluconazole
- Patients with renal or hepatic considerations that favor an echinocandin
The market outlook is structurally mature:
| Driver |
Direction for Eraxis |
| Generic anidulafungin |
Negative |
| Echinocandin class guidelines |
Positive for volume |
| Oral fluconazole step-down |
Negative for duration |
| Invasive candidiasis incidence |
Positive but epidemiologically variable |
| Candida auris |
Positive for demand, but resistant isolates may complicate use |
| Hospital purchasing pressure |
Negative for branded price |
| IV-only administration |
Negative versus oral alternatives |
| Antifungal stewardship |
Negative for prolonged therapy |
A reasonable commercial projection is flat-to-declining branded revenue, with unit demand partly offset by price erosion and generic substitution. The broader echinocandin market may grow with invasive fungal disease burden, critical-care utilization, and Candida auris management, but that growth does not translate proportionally into Eraxis sales.
How does Eraxis compare with Cancidas and Mycamine?
Eraxis competes directly with caspofungin and micafungin. All three drugs benefit from guideline preference for echinocandins in initial invasive-candidiasis treatment.
| Factor |
Eraxis |
Cancidas |
Mycamine |
| Active ingredient |
Anidulafungin |
Caspofungin |
Micafungin |
| Administration |
IV, once daily |
IV, once daily |
IV, generally once daily |
| Hepatic dose adjustment |
Usually not required |
Required in selected hepatic impairment |
Usually not required |
| Pediatric use |
Labeled |
Labeled |
Labeled |
| Generic pressure |
High |
High |
High |
| Main purchasing advantage |
Pharmacologic simplicity |
Established use and broad familiarity |
Broad institutional adoption |
| Main limitation |
IV-only therapy and mature pricing |
Hepatic dosing considerations |
Class-wide IV administration |
Eraxis can retain a formulary position where hospitals value simple dosing and low hepatic interaction burden. It has less leverage in contracts where generic acquisition price dominates.
What manufacturing and intellectual-property barriers remain?
Anidulafungin is a complex semisynthetic molecule. Manufacturing may require specialized fermentation-derived intermediates, chemical modification, purification, and sterile injectable production. These requirements can raise the technical threshold for a new manufacturer.
Manufacturing complexity does not equal patent exclusivity. A generic manufacturer can avoid an expired process patent by using a noninfringing process or a different supplier. The principal barriers are therefore:
- Technical development and impurity control
- Sterile injectable manufacturing capacity
- Stability and packaging validation
- Supply of key intermediates
- FDA inspection readiness
- Hospital contracting and distribution
- Demonstration of pharmaceutical equivalence
These barriers may limit the number of successful suppliers, but they do not support premium branded pricing once generic products are approved.
What generic entry risks exist for Eraxis?
The generic risk profile is high. The likely effects are:
- Lower net prices.
- Greater use of therapeutic interchange protocols.
- Reduced Pfizer bargaining power with hospitals.
- More aggressive formulary competition among echinocandins.
- Continued branded use only where procurement, physician familiarity, or supply reliability supports it.
A generic entrant does not need to reproduce the Eraxis brand. It needs to meet FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, manufacturing quality, and labeling.
What licensing deals affected Eraxis?
Anidulafungin originated in Lilly's development program, where it was known as LY303366. Pfizer later acquired commercial rights associated with Eraxis through its transaction with Lilly. The product's commercial history therefore reflects a licensing and portfolio-transfer model rather than a recent external partnership.
No major current licensing transaction appears to change the Eraxis competitive outlook. Regional commercialization arrangements may exist outside the United States, but they do not materially alter the product's mature, generic-exposed status.
What litigation or settlement agreements affect Eraxis?
No current litigation or settlement agreement has been identified as a material barrier to generic anidulafungin commercialization through June 2024. Historical patent disputes may have affected the timing of generic entry, but the present risk is primarily ordinary post-exclusivity competition.
The absence of a live litigation barrier reduces the probability of a delayed generic launch scenario. It also limits Pfizer's ability to use settlement terms or authorized-generic arrangements to preserve brand economics.
Key Takeaways
- Eraxis is an intravenous anidulafungin product approved by the FDA in 2006.
- Its main uses are invasive candidiasis and esophageal candidiasis.
- No major proprietary Phase 2 or Phase 3 lifecycle program is apparent through June 2024.
- The drug remains clinically relevant because guidelines recommend echinocandins for initial treatment of invasive candidiasis.
- Regulatory exclusivity and core patent protection have expired.
- Generic entry and hospital contracting create high risk for branded revenue.
- The broader echinocandin market may expand, but Eraxis is unlikely to capture that growth at branded pricing.
- Anidulafungin's low hepatic-interaction burden remains its strongest clinical differentiator.
- Manufacturing complexity can constrain supplier numbers but does not recreate meaningful composition-of-matter exclusivity.
- Eraxis has a mature, low-strength patent estate and a flat-to-declining branded commercial outlook.
FAQs About Eraxis and Anidulafungin
Is Eraxis still available in the United States?
Yes. Eraxis has been marketed in the United States, while generic anidulafungin products provide lower-cost alternatives.
Is anidulafungin active against Candida auris?
Activity depends on isolate susceptibility. Echinocandins are commonly recommended as initial therapy for susceptible Candida auris infections, but resistance testing and infectious-disease consultation are important because echinocandin-resistant isolates occur [5].
Can Eraxis be switched to fluconazole?
Yes, when the patient is clinically stable, the isolate is susceptible, repeat blood cultures are negative, and there is no contraindication to fluconazole. The decision follows guideline-based step-down criteria [3].
Does Eraxis require renal dose adjustment?
No routine renal dose adjustment is generally required, including in patients receiving hemodialysis, according to the U.S. prescribing information [1].
Is Eraxis interchangeable with micafungin or caspofungin?
The drugs occupy similar clinical roles but are not automatically interchangeable at the prescription level. Dosing, indication, organ-function considerations, hospital formulary rules, and local susceptibility data determine product selection.
References
- U.S. Food and Drug Administration. (2023). Eraxis (anidulafungin) prescribing information.
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Karchmer, A. W., Sobel, J. D., et al. (2007). Anidulafungin versus fluconazole for invasive candidiasis. New England Journal of Medicine, 356(24), 2472-2482.
- Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., et al. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Centers for Disease Control and Prevention. (2024). Clinical overview of Candida auris.
